These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ. Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293 [Abstract] [Full Text] [Related]
4. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA, Association of Hemophilia Clinic Directors of Canada. Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481 [Abstract] [Full Text] [Related]
6. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, Inbal A. Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997 [Abstract] [Full Text] [Related]
9. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Michiels JJ, van de Velde A, van Vliet HH, van der Planken M, Schroyens W, Berneman Z. Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235 [Abstract] [Full Text] [Related]
15. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures. Shortt J, Dunkley S, Rickard K, Baker R, Street A. Haemophilia; 2007 Mar; 13(2):144-8. PubMed ID: 17286766 [Abstract] [Full Text] [Related]
17. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate. Hernandez-Navarro F, Quintana M, Jimenez-Yuste V, Alvarez MT, Fernandez-Morata R. Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696 [Abstract] [Full Text] [Related]
18. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Foster PA. Thromb Haemost; 1995 Nov; 74(5):1370-8. PubMed ID: 8607125 [Abstract] [Full Text] [Related]
19. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Dean JA, Blanchette VS, Carcao MD, Stain AM, Sparling CR, Siekmann J, Turecek PL, Lillicrap D, Rand ML. Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962 [Abstract] [Full Text] [Related]
20. A comparative in vitro evaluation of six von Willebrand factor concentrates. Lethagen S, Carlson M, Hillarp A. Haemophilia; 2004 May; 10(3):243-9. PubMed ID: 15086321 [Abstract] [Full Text] [Related] Page: [Next] [New Search]